Sanibel Captiva Trust Company Inc. Sells 1,718 Shares of GSK plc (NYSE:GSK)

Sanibel Captiva Trust Company Inc. cut its stake in shares of GSK plc (NYSE:GSK) by 10.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 14,633 shares of the pharmaceutical company’s stock after selling 1,718 shares during the quarter. Sanibel Captiva Trust Company Inc.’s holdings in GSK were worth $495,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of GSK. Sunbelt Securities Inc. lifted its holdings in GSK by 73.8% during the 3rd quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock worth $29,000 after purchasing an additional 302 shares in the last quarter. EverSource Wealth Advisors LLC lifted its holdings in shares of GSK by 9.4% in the second quarter. EverSource Wealth Advisors LLC now owns 3,542 shares of the pharmaceutical company’s stock worth $137,000 after buying an additional 303 shares in the last quarter. Mesirow Financial Investment Management Inc. boosted its position in shares of GSK by 2.0% in the third quarter. Mesirow Financial Investment Management Inc. now owns 16,693 shares of the pharmaceutical company’s stock valued at $682,000 after acquiring an additional 323 shares during the period. Rehmann Capital Advisory Group grew its stake in GSK by 6.3% during the third quarter. Rehmann Capital Advisory Group now owns 5,608 shares of the pharmaceutical company’s stock valued at $232,000 after acquiring an additional 332 shares in the last quarter. Finally, Investment Partners Asset Management Inc. increased its holdings in GSK by 2.3% during the 3rd quarter. Investment Partners Asset Management Inc. now owns 15,559 shares of the pharmaceutical company’s stock worth $636,000 after acquiring an additional 344 shares during the period. 15.74% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on GSK. StockNews.com upgraded shares of GSK from a “buy” rating to a “strong-buy” rating in a research report on Monday, January 13th. Guggenheim cut GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. Jefferies Financial Group cut GSK from a “buy” rating to a “hold” rating and lowered their price target for the company from $53.00 to $39.50 in a report on Tuesday, November 12th. Finally, Deutsche Bank Aktiengesellschaft cut shares of GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Seven analysts have rated the stock with a hold rating and four have issued a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $43.25.

GSK Price Performance

Shares of NYSE:GSK opened at $33.46 on Monday. The company has a quick ratio of 0.53, a current ratio of 0.81 and a debt-to-equity ratio of 0.98. The stock has a market cap of $69.34 billion, a PE ratio of 21.72, a PEG ratio of 1.44 and a beta of 0.63. The company’s fifty day moving average is $34.02 and its 200 day moving average is $37.98. GSK plc has a 52 week low of $31.72 and a 52 week high of $45.92.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, January 9th. Stockholders of record on Friday, November 15th were issued a $0.3928 dividend. The ex-dividend date of this dividend was Friday, November 15th. This represents a $1.57 annualized dividend and a dividend yield of 4.70%. This is an increase from GSK’s previous quarterly dividend of $0.38. GSK’s payout ratio is currently 96.10%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.